Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Blending science and compassion: The 30th educational symposium of the Society of Critical Care Medicine, San Francisco, USA, 10–14 February 2001"
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Blending science and compassion: The 30th educational symposium of the Society of Critical Care Medicine, San Francisco, USA, 10–14 February 2001. | Available online http ccforum.eom content 5 2 072 Meeting report Blending science and compassion The 30th educational symposium of the Society of Critical Care Medicine San Francisco USA 10-14 February 2001 David Smith BioMed Central 34-42 Middlesex House Cleveland St London UK Received 28 February 2001 Revisions requested 2 March 2001 Revisions received 2 March 2001 Accepted 2 March 2001 Published 7 March 2001 Critical Care 2001 5 72-76 2001 BioMed Central Ltd Print ISSN 1364-8535 Online ISSN 1466-609X Introduction This year s symposium was dominated by two major themes. The first was the unveiling of the results of the phase II clinical trial on the use of recombinant human activated protein C rhAPC in the treatment of sepsis. For the first time in 30 years a major breakthrough has been achieved and the result is all the more welcome given that recombinant antithrombin III was recently shown to be of no use in the treatment of sepsis. The second major theme was the need to educate physicians in the nuances of patient outcome in the intensive care unit ICU . For a long time the philosophy has been to treat the patient as an object to be repaired. Now however we have the ability to prevent death in the majority of cases but to what end Statistics from the USA show that about 20 of patients admitted to the ICU die there. The important point is that 70 to 90 of those deaths are the result of a conscious decision to withhold or withdraw treatment. The issues of quality of life after treatment and at the end of life in the ICU were also discussed. Results of the Phase III rhAPC multicentre placebo controlled trial Presented by J-L Vincent G Bernard D Angus and S La Rosa As researchers have refined their understanding of the many biochemical pathways involved in sepsis they have identified new targets for developing potentially effective treatments. So far the search for drugs has been a frustrating one. More than 30 clinical trials of investigational compounds for the